WEKO3
アイテム
{"_buckets": {"deposit": "76c6aa7d-9ce2-4dcf-baae-4d72ed19799a"}, "_deposit": {"created_by": 2, "id": "16335", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "16335"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00016335", "sets": ["30"]}, "author_link": ["61703", "61717", "61720", "61716", "61710", "61711", "61721", "61718", "61719", "61712", "61727", "61708", "61713", "61724", "61714", "61715", "61729", "61723", "61728", "61722", "61704", "61707", "61709", "61706", "61725", "61726", "61705"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2009-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "492", "bibliographicPageStart": "488", "bibliographicVolumeNumber": "19", "bibliographic_titles": [{"bibliographic_title": "Modern rheumatology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We tried to determine which baseline variables are responsible for remission induction at 6 months in unselected rheumatoid arthritis (RA) patients of Japanese population treated with etanercept. One hundred forty-one patients with RA who were administered etanercept were registered. Thirty-four patients were started on etanercept monotherapy, 60 patients on cotherapy with methotrexate (MTX) (MTX cotherapy), and 47 patients on cotherapy with other non-MTX nonbiologic disease-modifying antirheumatic drugs (DMARDs) (non-MTX cotherapy). None of the patients were treated with both MTX and non-MTX nonbiologic DMARDs at entry. Outcome was set as achievement of disease activity score 28 (DAS28)-ESR remission at 6 months. We examined association of gender, DAS at baseline, MTX cotherapy at baseline, non-MTX cotherapy at baseline, and prednisolone use at baseline with achievement of remission at 6 months by logistic regression analysis. All subjects were classified as having high (N = 109) or moderate disease activity (N = 32) at entry. One hundred twenty out of 141 patients (85.1%) continued treatment with etanercept at 6 months. Continuation rate was statistically higher in MTX cotherapy (93.3%) compared with etanercept monotherapy (73.5%), and tended to be higher than with non-MTX cotherapy (85.1%). Logistic regression analysis identified that MTX cotherapy at entry and moderate disease activity at entry were independent variables for remission induction at 6 months. Accordingly, DAS28-ESR at 6 months was significantly lower with MTX cotherapy as compared with etanercept monotherapy or non-MTX cotherapy. To a lesser extent, DAS28-ESR with non-MTX cotherapy at 6 months was lower than with etanercept monotherapy. In this study of unselected patients, use of MTX and moderate disease activity at entry were associated with higher likelihood of response to etanercept. Non-MTX nonbiologic DMARDs may be an alternative in RA patients administrated etanercept who are intolerant to MTX.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Modern Rheumatology, 19(5), pp.488-492; 2009", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本リウマチ学会"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "19578932", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s10165-009-0187-8", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c Japan College of Rheumatology 2009"}, {"subitem_rights": "利用は著作権の範囲内に限られる。"}, {"subitem_rights": "The original publication is available at www.springerlink.com"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA1157187X", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14397595", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14397609", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "Japan College of Rheumatology"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Iwamoto, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "61703", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "61704", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujikawa, Keita"}], "nameIdentifiers": [{"nameIdentifier": "61705", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aramaki, Toshiyuki"}], "nameIdentifiers": [{"nameIdentifier": "61706", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawashiri, Shin-Ya"}], "nameIdentifiers": [{"nameIdentifier": "61707", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tamai, Mami"}], "nameIdentifiers": [{"nameIdentifier": "61708", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Arima, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "61709", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichinose, Kunihiro"}], "nameIdentifiers": [{"nameIdentifier": "61710", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamachi, Makoto"}], "nameIdentifiers": [{"nameIdentifier": "61711", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamasaki, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "61712", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "61713", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakashima, Munetoshi"}], "nameIdentifiers": [{"nameIdentifier": "61714", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizokami, Akinari"}], "nameIdentifiers": [{"nameIdentifier": "61715", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Goto, Akiko"}], "nameIdentifiers": [{"nameIdentifier": "61716", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Takaaki"}], "nameIdentifiers": [{"nameIdentifier": "61717", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuoka, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "61718", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ueki, Yukitaka"}], "nameIdentifiers": [{"nameIdentifier": "61719", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukada, Toshiaki"}], "nameIdentifiers": [{"nameIdentifier": "61720", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Migita, Kiyoshi"}], "nameIdentifiers": [{"nameIdentifier": "61721", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shoumura, Fumiko"}], "nameIdentifiers": [{"nameIdentifier": "61722", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawabe, Yojiro"}], "nameIdentifiers": [{"nameIdentifier": "61723", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibatomi, Kazutaka"}], "nameIdentifiers": [{"nameIdentifier": "61724", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mine, Masanobu"}], "nameIdentifiers": [{"nameIdentifier": "61725", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ida, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "61726", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Origuchi, Tomoki"}], "nameIdentifiers": [{"nameIdentifier": "61727", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aoyagi, Kiyoshi"}], "nameIdentifiers": [{"nameIdentifier": "61728", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eguchi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "61729", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-23"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ModRhe19_488.pdf", "filesize": [{"value": "163.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 163400.0, "url": {"label": "ModRhe19_488.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/16335/files/ModRhe19_488.pdf"}, "version_id": "11758c64-31da-4e6b-9545-faaddd40260b"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "DAS28-ESR", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Etanercept", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MTX", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-MTX nonbiologic DMARDs", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Rheumatoid arthritis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/31174", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-04-03"}, "publish_date": "2013-04-03", "publish_status": "0", "recid": "16335", "relation": {}, "relation_version_is_last": true, "title": ["Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population"], "weko_shared_id": 2}
Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population
http://hdl.handle.net/10069/31174
http://hdl.handle.net/10069/31174f3215cc6-444b-4287-bcce-23cbe2478952
名前 / ファイル | ライセンス | アクション |
---|---|---|
ModRhe19_488.pdf (163.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-04-03 | |||||
タイトル | ||||||
タイトル | Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | DAS28-ESR | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Etanercept | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | MTX | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Non-MTX nonbiologic DMARDs | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Rheumatoid arthritis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Iwamoto, Naoki
× Iwamoto, Naoki× Kawakami, Atsushi× Fujikawa, Keita× Aramaki, Toshiyuki× Kawashiri, Shin-Ya× Tamai, Mami× Arima, Kazuhiko× Ichinose, Kunihiro× Kamachi, Makoto× Yamasaki, Satoshi× Nakamura, Hideki× Nakashima, Munetoshi× Mizokami, Akinari× Goto, Akiko× Fukuda, Takaaki× Matsuoka, Naoki× Ueki, Yukitaka× Tsukada, Toshiaki× Migita, Kiyoshi× Shoumura, Fumiko× Kawabe, Yojiro× Shibatomi, Kazutaka× Mine, Masanobu× Ida, Hiroaki× Origuchi, Tomoki× Aoyagi, Kiyoshi× Eguchi, Katsumi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We tried to determine which baseline variables are responsible for remission induction at 6 months in unselected rheumatoid arthritis (RA) patients of Japanese population treated with etanercept. One hundred forty-one patients with RA who were administered etanercept were registered. Thirty-four patients were started on etanercept monotherapy, 60 patients on cotherapy with methotrexate (MTX) (MTX cotherapy), and 47 patients on cotherapy with other non-MTX nonbiologic disease-modifying antirheumatic drugs (DMARDs) (non-MTX cotherapy). None of the patients were treated with both MTX and non-MTX nonbiologic DMARDs at entry. Outcome was set as achievement of disease activity score 28 (DAS28)-ESR remission at 6 months. We examined association of gender, DAS at baseline, MTX cotherapy at baseline, non-MTX cotherapy at baseline, and prednisolone use at baseline with achievement of remission at 6 months by logistic regression analysis. All subjects were classified as having high (N = 109) or moderate disease activity (N = 32) at entry. One hundred twenty out of 141 patients (85.1%) continued treatment with etanercept at 6 months. Continuation rate was statistically higher in MTX cotherapy (93.3%) compared with etanercept monotherapy (73.5%), and tended to be higher than with non-MTX cotherapy (85.1%). Logistic regression analysis identified that MTX cotherapy at entry and moderate disease activity at entry were independent variables for remission induction at 6 months. Accordingly, DAS28-ESR at 6 months was significantly lower with MTX cotherapy as compared with etanercept monotherapy or non-MTX cotherapy. To a lesser extent, DAS28-ESR with non-MTX cotherapy at 6 months was lower than with etanercept monotherapy. In this study of unselected patients, use of MTX and moderate disease activity at entry were associated with higher likelihood of response to etanercept. Non-MTX nonbiologic DMARDs may be an alternative in RA patients administrated etanercept who are intolerant to MTX. | |||||
書誌情報 |
Modern rheumatology 巻 19, 号 5, p. 488-492, 発行日 2009-10 |
|||||
出版者 | ||||||
出版者 | 日本リウマチ学会 | |||||
出版者別言語 | ||||||
Japan College of Rheumatology | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14397595 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14397609 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA1157187X | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 19578932 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s10165-009-0187-8 | |||||
権利 | ||||||
権利情報 | c Japan College of Rheumatology 2009 | |||||
権利 | ||||||
権利情報 | 利用は著作権の範囲内に限られる。 | |||||
権利 | ||||||
権利情報 | The original publication is available at www.springerlink.com | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Modern Rheumatology, 19(5), pp.488-492; 2009 |